Piramal Pharma Limited announced the approval of its unaudited standalone financial results for the quarter and half year ended September 30, 2026. The Board of Directors convened on October 27, 2026, to ratify these results. Key figures include a total income of ₹1,483.31 crore for the quarter and a net profit after tax of ₹170.74 crore. The half-yearly results also show robust performance with total income of ₹2,722.89 crore and a net profit after tax of ₹284.22 crore.
Piramal Pharma Board Approves Q2 FY27 Financials
Piramal Pharma Limited has officially announced the approval of its unaudited standalone financial results for both the quarter and the half year ended September 30, 2026. The company’s Board of Directors met on October 27, 2026, to review and approve these crucial financial statements.
Financial Highlights – Standalone Results
Quarter Ended September 30, 2026:
- Total Income: ₹1,483.31 crore
- Profit Before Tax: ₹224.60 crore
- Net Profit After Tax: ₹170.74 crore
Half Year Ended September 30, 2026:
- Total Income: ₹2,722.89 crore
- Profit Before Tax: ₹374.08 crore
- Net Profit After Tax: ₹284.22 crore
The results also detail significant figures for other comprehensive income (OCI). The meeting, which commenced at 5:30 PM and concluded at 8:30 PM, also saw the board approve the company’s consolidated financial results for the same periods.
Unaudited Consolidated Financial Results
The consolidated financial results for the quarter ended September 30, 2026, indicate a total income of ₹2,652.99 crore and a net profit after tax of ₹5.03 crore. For the half year ended September 30, 2026, the consolidated total income stood at ₹5,012.32 crore, with a net profit after tax of (₹64.35) crore.
In addition to the financial results, the company has also arranged for the publication of these results in newspapers, as required by SEBI Listing Regulations. The information is also available on the company’s website, www.piramalpharma.com.
Source: BSE
